Visceral leishmaniasis follow-up and treatment outcomes in Tiaty East and West sub-counties, Kenya: Cure, relapse, and Post Kala-azar Dermal Leishmaniasis
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0306067 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Grace C Kennedy und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, MA, United States of America. Hauptthemen laut MEDLINE: Leishmaniasis, Visceral, Recurrence. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Northeastern University.
Abstract (Originalsprache)
Background Visceral Leishmaniasis (VL) is a neglected tropical disease (NTD) with the highest regional burden in East Africa. Relapse and Post Kala-azar Dermal Leishmaniasis (PKDL) contribute to the spread of VL in endemic areas, making their surveillance imperative for control and elimination. Little is known about long-term patient outcomes in Kenya through follow-up after VL treatment, despite its requirement for control and elimination by the World Health Organization (WHO) and the Kenya Ministry of Health (KMOH). Methodology/Principal findings 36 follow-up patients in Tiaty East and West, sub-counties, Kenya, and records from 248 patients at the regional Chemolingot Sub-county Hospital (CSCH) were analyzed separately using Fisher’s Exact Tests, two-sample t-tests, and Welch’s t-tests in R (Version 4.3.0). The study found a prevalence rate of 88.89% (n = 32) final cure, 5.56% (n = 2) relapse, and 5.56% (n = 2) PKDL in follow-up patients and 92.74% (n = 230) initial cure, 6.86% (n = 17) relapse, and 0.80% (n = 2) PKDL in overall CSCH patients. The mean lengths of time at which follow-up patients relapsed and developed PKDL were 4.5 and 17 months, respectively. Young age (p = 0.04, 95% CI 0.63–24.31), shorter length of time from initial treatment to follow-up (p = 0.002, 95% CI 1.03-∞), lower Hb level at primary treatment (p = 0.0002, 95% CI 1.23–3.24), and living in Tiaty East sub-county (p = 0.04, 95% CI 0.00–1.43) were significantly associated (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Sciences, Bouvé College of Health Sciences, Northeastern University, Boston, MA, United States of America.
- African Center for Community Investment in Health, Chemolingot, Baringo County, Kenya.
- Chemolingot Sub-County Hospital, Chemolingot, Baringo County, Kenya.
- Department of Cultures, Societies and Global Studies, College of Social Sciences and Humanities, Northeastern University, Boston, MA, United States of America.
- Integrated Initiative for Global Health, Northeastern University, Boston, MA, United States of America.
- Nigerian Institute of Medical Research, Lagos, Nigeria.
ORCID-Profile: Grace C Kennedy
Förderung
- Northeastern University
Zitieren
APA
Kennedy, G. C., O'Brien, K., Nyakundi, H., Kitondo, M., Biwott, W., & Wamai, R. G. (2024). Visceral leishmaniasis follow-up and treatment outcomes in Tiaty East and West sub-counties, Kenya: Cure, relapse, and Post Kala-azar Dermal Leishmaniasis. PLOS ONE. https://doi.org/10.1371/journal.pone.0306067
Vancouver
Kennedy GC, O'Brien K, Nyakundi H, Kitondo M, Biwott W, Wamai RG. Visceral leishmaniasis follow-up and treatment outcomes in Tiaty East and West sub-counties, Kenya: Cure, relapse, and Post Kala-azar Dermal Leishmaniasis. PLOS ONE. 2024. doi:10.1371/journal.pone.0306067
BibTeX
@article{Kennedy2024,
author = {Kennedy, Grace C and O'Brien, Katherine and Nyakundi, Hellen and Kitondo, Mwatela and Biwott, Wilson and Wamai, Richard G},
title = {Visceral leishmaniasis follow-up and treatment outcomes in Tiaty East and West sub-counties, Kenya: Cure, relapse, and Post Kala-azar Dermal Leishmaniasis},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0306067}
}
EUVIMED